Innate Pharma S.A. (IPHA)

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Target Price of $6.67

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma Q2 Earnings Call Highlights

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

Innate Pharma Announces Conference Call and Webcast

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)